Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
In the USA, Tengion has a Neo-Kidney augment program submitting for FDA human trial sometime this year!
I Second that nomination...
4-5 eastern?
Thanks North!
This might be a little OT, does any one know of a compassionate use trial for someone with stage 4 pancreatic cancer?
I agree, I think the TOS allow for anything to be said about a stock, but does not allow for anything to be said about a poster, a technical thing, just like the legal renderings vs ACTC. They win and lose based on technical language, not really based on what is seemingly right in a moral way. IMO ACTC may have some advantage in this area with a couple of the remaining cases.
Last year at this time many of us speculated on the coming years PPS. Some of us were conservative and said about 50 cents per share, some were as high as $10 per share. Hopefully we were off by a year.
http://grants.nih.gov/stem_cells/registry/pending.htm
Check that link above. The NIH site, you will find ACTC in there in their Pending Review page.
The company is conducting a total of three clinical trials in the U.S. and Europe. Each trial will enroll a total of 12 patients, with cohorts of three patients in an ascending dosage format. These trials are prospective, open-label studies designed to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation into patients with dry AMD or SMD at 12 months, the study’s primary endpoint. Preliminary results from the two U.S. trials were reported in The Lancet earlier this year.
“Completing the higher-cell dosage in both our U.S. trials is an important milestone in our clinical programs,” said Robert Lanza, M.D., ACT’s chief scientific officer. “We are now halfway through both U.S. trials, and look forward to treating the remaining two patient cohorts in the coming year.”
Added Dr. Eliott, “Dry AMD affects upwards of 30 million people worldwide. Moreover, it has no approved drug treatment available to date. ACT’s hESC-derived RPE cells could address this considerable unmet need and also point the way towards treatments of other forms of macular degeneration. We are pleased to be a part of this important clinical trial.”
Happy to see Rocky's clarity.
I think you might be mistaken...It's the best financing ever for ACTC.
Interesting blog by Hill...no mention of ACTC trial...but there is a promotion at the end for a company that provides some sort of visual aid technology.
Here are the lines awaiting approval at NIH:
MA 09 Advanced Cell Technology, Inc. 12/30/2009
MA 42 Advanced Cell Technology, Inc. 02/04/2010
MA 50 Advanced Cell Technology, Inc. 02/04/2010
NED 1 Advanced Cell Technology, Inc. 12/24/2009
NED 2 Advanced Cell Technology, Inc. 12/24/2009
NED 3 Advanced Cell Technology, Inc. 12/24/2009
NED 4 Advanced Cell Technology, Inc. 12/24/2009
A super thing to look for is the NIH announcement, I think Thursday or Friday. I've felt a lot more unsure about ACTC in the past, I think they've got A/G thing, then the Camofi, and possibly in a year the SEC thing in a year or less. If you are long time holder, set an alert with your broker to tell you when to open your eyes again as in a rise in the PPS. My feeling is, better times are closer than they were.
Aronson Gorton, I assume, are the plantiffs. Wasn't their first claim deceided on and dismissed with prejudice? I guess the sentiment here is that these too will go the same route, lets hope so as we wait and see.
Pfizer....Their trial is for wet amd, yes? If yes is so, then Pfizer is running a complimentary trial.
"In fairness to Gary Rabin, Dr. Schwartz spoke of him in glowing terms and I would imagine he has dealt with a number of CEO and executive level officers in a good many of the trials he has done at JSEI. I can think of no reason that he would be so complimentary if it was not deserved."
Yes I agree. Recount all the positive things that have happened, give some credit where it is due.
Looking pretty good. Thanks for your unbiased posting!
Thank you Rocky. It seems that NIH approval would still be of some great benefit for ACT.
Foundation Fighting Blindness....I've not heard of that organization till now.
Not concerned, increased acuity is noted.
From CC Gary R. "In order to qualify, we must settle a litigation with our warrant holders in the SEC. With respect to the Warrant holders, we have settled with one of the holders. We continue to negotiate with the remaining investor with a goal of reaching a settlement, but we are not going to make a bad deal for shareholders for the sole reason of listing on the NASDAQ."
I wonder who was settled with, and who remains?
I don't think you can have increased visual acuity without engraftment. They have said there was increased visual acuity in the AMD trial. The area represented by 50K cells is smaller than a period at the end of this sentence.
yes, it has been listed in the near top of list things they will address.
http://www.advancedcell.com/documents/0000/0423/act-corporate-presentation--mesa-meeting---october-2012.pdf
Look at slide 29 regarding Ocular Programs.
pretty quite today...holding steady....JK
Of course with out the contributions of ACTC personal, there would be zero value and nothing to talk about, and eventually nothing to celebrate...with positive activity in the trials, the rest is what it is, IMO the wind will pick up again and fill the sail...and such can't be said for many biotechs.
Hardcore holder here...some treat ACTC shares like a thing they buy at a garage sale in hopes of selling it for a quick cent at their own...not realizing that they have a masterpiece in their hands, just awaiting the correct appraisal.
A Supreme Human Being
Let us praise his name then, as a supreme human being.
cue: glory music
ACTC will rise like a phoenix
cue: Timpani Drum
I see a Nobel prize in the future for ACTC
Ignore the money changers and stand strong with the vision changers!
Unite! pound three times on table we shall never relinquish!
cue: glory music
ACTC will rise like a phoenix
cue: Timpani Drum
I see a Nobel prize in the future for ACTC
Ignore the money changers and stand strong with the vision changers!
Unite! pound three times on table we shall never relinquish!
What was it not too long ago, the Alpha shares were released? Must be...
I guess investors hub doesn't track this stock daily
You can tell the biased posts VS the posts that are unbiased. I don't hope to convert posters with a wholly negative content, they have their reasons.$$. An unbiased realization admits that companies and investors have to borrow, just like any business and without some investment there would be no progress. The progress leads to the increase in value vs. the cost of attaining the value. Anyone who has studied ACTC knows the big time value targets they are approaching. The approaching increased value will translate to the all important price per share increase, even without the holy grail of revenue that some poster keep insisting is the only source of value. I hope the harping on the revenue topic is closed.
You see things as exceedingly dark. Why? Lanza publishing, how can that be bad? Scholars who are capable often publish, if they are able. The financing can be seen as adding to their position of strength in the area of JV negotiating, as they are not seen as desperate. Exceedingly good results so far in trials. This judgement was released after hours friday, so if its a bump in the pps, it would have to happen subsequently. "SEC breathing down their necks" I'd hardly characterize it that way, ACTC just wants the details on what went down back then. I wouldn't expect any conclusion to this until late next year or the following year 2014. Camofi awaits, is there really any other case, not that I know of. Daylight ahead. Get a copy of Fortune magazine and read the article. Sorry if you are an ACTC hater, if not, live long, prosper...
This official news regards the current conclusion to the Aronson Gorton case...remember, they're all seperate, because they have different contract details and are different finance companies. Its in ACTC favor, from my understanding. Seek out rocky's corner on Investorstemcell.com for a deeper understanding. BTW, if its in ACTC's favor, I would think that means no shares going from ACTC to them.
From Rockys corner....good news for ACTC
Judge Rules in Aronson/Gorton Case:
IMO, this states that the "Report" issued by Judge Magistrate stands as written.
A/G OBJECTION considered and "Report" is adopted, objection denied..
09/28/2012 Judge Nathaniel M. Gorton: ORDER entered. ORDER ON REPORT AND RECOMMENDATIONS Action on motion: ; granting 37 Motion to Dismiss; granting in part and denying in part 38 Motion to Dismiss; granting 13 Motion to Dismiss; granting in part and denying in part 19 Motion to Dismiss; adopting Report and Recommendations re 47 Report and Recommendations. "Because of the coincidence and uncommonness of the names of one of the plaintiffs and the presiding judicial officer, the parties are advised that said judicial officer is neither related to nor acquainted with that plaintiff. After consideration of plaintiffs' objections thereto (Docket No. 48 ), Report and Recommendation is accepted and adopted." (Moore, Kellyann) (Entered: 09/28/2012)
What's the joke?
A JV with the complimentary talent, I agree, would create a value beyond the solitary 100% situation. Thank you for the perspective. If the partner offers these advantages, then true value will increase. Yes, then we may see a substantial rise in value in the near term.
I think the procedure might even end up in a Lacik like situation, could even be done by a computer controlled surgical device.